Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b<sup>+/−</sup>mice

  • Akiko Ohi
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Etsuyo Hanabusa
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Otoya Ueda
    Chugai Pharmaceutical Company, Limited, and
  • Hiroko Segawa
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Naoshi Horiba
    Chugai Pharmaceutical Company, Limited, and
  • Ichiro Kaneko
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Shoji Kuwahara
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Tomo Mukai
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Shohei Sasaki
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Rieko Tominaga
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Junya Furutani
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Fumito Aranami
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Shuichi Ohtomo
    Chugai Pharmaceutical Company, Limited, and
  • Yumiko Oikawa
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Yousuke Kawase
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Naoko A. Wada
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Takanori Tachibe
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Mami Kakefuda
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Hiromi Tateishi
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Kaoru Matsumoto
    Chugai Research Institute for Medical Science, Incorporated, Tokyo, Japan
  • Sawako Tatsumi
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Shinsuke Kido
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and
  • Naoshi Fukushima
    Chugai Pharmaceutical Company, Limited, and
  • Kou-ichi Jishage
    Chugai Pharmaceutical Company, Limited, and
  • Ken-ichi Miyamoto
    Department of Molecular Nutrition Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima City; and

書誌事項

公開日
2011-11
資源種別
journal article
DOI
  • 10.1152/ajprenal.00663.2010
公開者
American Physiological Society

この論文をさがす

説明

<jats:p>An inorganic phosphate (P<jats:sub>i</jats:sub>)-restricted diet is important for patients with chronic kidney disease and patients on hemodialysis. Phosphate binders are essential for preventing hyperphosphatemia and ectopic calcification. The sodium-dependent P<jats:sub>i</jats:sub>(Na/P<jats:sub>i</jats:sub>) transport system is involved in intestinal P<jats:sub>i</jats:sub>absorption and is regulated by several factors. The type II sodium-dependent P<jats:sub>i</jats:sub>transporter Npt2b is expressed in the brush-border membrane in intestinal epithelial cells and transports P<jats:sub>i</jats:sub>. In the present study, we analyzed the phenotype of Npt2b<jats:sup>−/−</jats:sup>and hetero<jats:sup>+/−</jats:sup>mice. Npt2b<jats:sup>−/−</jats:sup>mice died in utero soon after implantation, indicating that Npt2b is essential for early embryonic development. At 4 wk of age, Npt2b<jats:sup>+/−</jats:sup>mice showed hypophosphatemia and low urinary P<jats:sub>i</jats:sub>excretion. Plasma fibroblast growth factor 23 levels were significantly decreased and 1,25(OH)<jats:sub>2</jats:sub>D<jats:sub>3</jats:sub>levels were significantly increased in Npt2b<jats:sup>+/−</jats:sup>mice compared with Npt2b<jats:sup>+/+</jats:sup>mice. Npt2b mRNA levels were reduced to 50% that in Npt2b<jats:sup>+/+</jats:sup>mice. In contrast, renal Npt2a and Npt2c transporter protein levels were significantly increased in Npt2b<jats:sup>+/−</jats:sup>mice. At 20 wk of age, Npt2b<jats:sup>+/−</jats:sup>mice showed hypophosphaturia and reduced Na/P<jats:sub>i</jats:sub>cotransport activity in the distal intestine. Npt2b<jats:sup>+/+</jats:sup>mice with adenine-induced renal failure had hyperphosphatemia and high plasma creatinine levels. Npt2b<jats:sup>+/−</jats:sup>mice treated with adenine had significantly reduced plasma P<jats:sub>i</jats:sub>levels compared with Npt2b<jats:sup>+/+</jats:sup>mice. Intestinal Npt2b protein and Na<jats:sup>+</jats:sup>/P<jats:sub>i</jats:sub>transport activity levels were significantly lower in Npt2b<jats:sup>+/−</jats:sup>mice than in the Npt2b<jats:sup>+/+</jats:sup>mice. The findings of the present studies suggest that Npt2b is an important target for the prevention of hyperphosphatemia.</jats:p>

収録刊行物

被引用文献 (18)*注記

もっと見る

参考文献 (41)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ